Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024.
Juliette PaireauCécile DurandSylvain C RaimbaultJoséphine CazaubonGuillaume MortametDelphine ViriotChristophe MilesiElise Daudens-VaysseDominique PloinSabrina TessierNoémie VanelJean-Loup ChappertKarine LevieuxRonan OllivierJamel DaoudiBruno CoignardStéphane LeteurtreIsabelle Parent-du-ChâteletSophie VauxPublished in: Influenza and other respiratory viruses (2024)
In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case-control study based on the test-negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5-88.7) in the main analysis and 80.6% (61.6-90.3) and 80.4% (61.7-89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.